Aura Biosciences, Inc. AURA Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.19M-22.9% | $1.54M-14.9% | $1.82M+8.2% | $1.68M+5.3% | $1.59M-21.6% | ||
| $27.96M+27.7% | $21.9M-1.3% | $22.18M-3.1% | $22.88M-2.0% | $23.34M+4.5% | ||
| $6.91M+29.3% | $5.34M-6.8% | $5.73M-0.1% | $5.73M+0.7% | $5.69M+4.0% | ||
| $34.87M+28.0% | $27.24M-2.4% | $27.91M-2.5% | $28.61M-1.5% | $29.04M+4.4% | ||
| -$34.87M-28.0% | -$27.24M+2.4% | -$27.91M+2.5% | -$28.61M+1.5% | -$29.04M-4.4% | ||
| $1.19M-29.6% | $1.69M-6.0% | $1.8M+9.7% | $1.64M+4.6% | $1.57M-21.4% | ||
| -$33.67M-31.8% | -$25.54M+2.1% | -$26.1M+3.2% | -$26.97M+1.8% | -$27.47M-6.4% | ||
| $11K-26.7% | $15K-42.3% | $26K-45.8% | $48K+167% | $18K-25.0% | ||
| -$33.69M-31.8% | -$25.56M+2.2% | -$26.13M+3.3% | -$27.02M+1.7% | -$27.48M-6.4% | ||
| -$0.50-35.1% | -$0.37+7.5% | -$0.40+14.9% | -$0.47+14.5% | -$0.55-5.8% | ||
| -$0.50-35.1% | -$0.37+7.5% | -$0.40+14.9% | -$0.47+14.5% | -$0.55-5.8% | ||
| 67.4M+11.8% | 60.3M-8.5% | 65.9M+13.7% | 58M+15.7% | 50.1M+1.0% | ||
| 67.4M+11.8% | 60.3M-8.5% | 65.9M+13.7% | 58M+15.7% | 50.1M+1.0% | ||
| -$33.79M-31.3% | -$25.73M+1.4% | -$26.09M+3.7% | -$27.1M+2.0% | -$27.64M-5.6% | ||
| $1.19M-22.9% | $1.54M-14.9% | $1.82M+8.2% | $1.68M+5.3% | $1.59M-21.6% | ||
| -$78K-609% | -$11K-119% | $57K+165% | -$88K+35.8% | -$137K+59.6% | ||
| -$27K+83.1% | -$160K-1,131% | -$13K-263% | $8K+138% | -$21K-1,580% | ||
| $2K-98.7% | $149K+1,246% | -$13K+63.9% | -$36K-50.0% | -$24K+35.1% | ||
| -$34.87M-28.0% | -$27.24M+2.4% | -$27.91M+2.5% | -$28.61M+1.5% | -$29.04M-4.4% | ||
| -$34.59M-28.3% | -$26.97M+2.3% | -$27.61M+2.5% | -$28.31M+1.5% | -$28.74M-4.5% | ||
| -$34.59M-28.3% | -$26.97M+2.3% | -$27.61M+2.5% | -$28.31M+1.5% | -$28.74M-4.5% | ||
| -$34.87M-28.0% | -$27.24M+2.4% | -$27.91M+2.5% | -$28.61M+1.5% | -$29.04M-4.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Aura Biosciences, Inc. profitable?
- Aura Biosciences, Inc. is not currently profitable: it reported a net loss of $112.4M over the trailing twelve months.
- What is Aura Biosciences, Inc.'s earnings per share?
- Aura Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-1.74.
- Where does Aura Biosciences, Inc.'s income statement data come from?
- Every line is extracted from Aura Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.